Rarβ expression in keratinocytes from potentially malignant oral lesions : the functional consequences of re-expression by de-methylating agents

Show simple item record

dc.contributor.author Radhakrishnan, Raghu
dc.contributor.author Crane, Hannah L.
dc.contributor.author Daigneault, Marc
dc.contributor.author Ram Padam, Kanaka Sai
dc.contributor.author Hunter, K.D. (Keith)
dc.date.accessioned 2022-02-09T12:06:04Z
dc.date.available 2022-02-09T12:06:04Z
dc.date.issued 2021-08-12
dc.description ADDITIONAL FILE 1: Figure S1: Expression of cRBP1 under AZA-C and ATRA treatment as assessed by qPCR. The pattern of expression in D19 is very similar to that in D34. en_ZA
dc.description ADDITIONAL FILE 2: Original blots and gels - all figures revised en_ZA
dc.description.abstract Loss of RARβ2 expression by promoter methylation is an early event in oral carcinogenesis. Understanding the mechanisms and consequences of RARβ loss may aid in understanding the disappointing results of retinoid chemoprevention trials. This study aimed to describe the effects of all-trans retinoic acid (ATRA) and the de-methylating agent 5-Aza-2' deoxycytidine (5-AZA-CdR) on a panel of immortal potentially malignant oral lesion (PMOL) cell cultures. RARβ expression was assessed in PMOL tissues by immunohistochemistry. Cells were treated with ATRA ± 5-AZA-CdR, and the effects on the cell cycle and senescence were assessed. In PMOL tissues, RARβ expression was variable, but lower in biopsies which gave rise to immortal cell cultures. Treatment of iPMOL cells with ATRA resulted in little change in RARβ expression, but the addition of 5-AZA-CdR resulted in significant increases. The effects on the cell cycle and senescence were variable and may be related to 5-AZA-CdR, as this has wider effects on the cell cycle. Overall, the response of iPMOL cells to ATRA and 5-AZA-CdR treatment was variable and is dependent on several factors, including RARβ-promoter methylation. These findings may help to explain the lack of consistent effect of retinoids in PMOLs seen in chemoprevention trials. en_ZA
dc.description.department Oral Pathology and Oral Biology en_ZA
dc.description.librarian am2022 en_ZA
dc.description.sponsorship This research was funded by the European Commission FP7 Marie Curie Incoming Fellowship, grant number PIIF-GA-2012-327300. en_ZA
dc.description.sponsorship The European Commission FP7 Marie Curie Incoming Fellowship en_ZA
dc.description.uri https://www.mdpi.com/journal/cancers en_ZA
dc.identifier.citation Radhakrishnan, R.; Crane, H.L.; Daigneault, M.; Padam, K.S.R.; Hunter, K.D. Rarβ expression in keratinocytes from potentially malignant oral lesions: the functional consequences of re-expression by de-methylating agents. Cancers 2021, 13, 4064. https://DOI.org/ 10.3390/cancers13164064. en_ZA
dc.identifier.issn 2072-6694 (online)
dc.identifier.other 10.3390/ cancers13164064
dc.identifier.uri http://hdl.handle.net/2263/83733
dc.language.iso en en_ZA
dc.publisher MDPI en_ZA
dc.rights © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. en_ZA
dc.subject Oral cancer en_ZA
dc.subject Oral potentially malignant lesions en_ZA
dc.subject Retinoids en_ZA
dc.subject Chemoprevention en_ZA
dc.subject All-trans retinoic acid (ATRA) en_ZA
dc.subject RARβ2 en_ZA
dc.subject Potentially malignant oral lesion (PMOL) en_ZA
dc.subject De-methylating agent 5-Aza-2′ deoxycytidine (5-AZA-CdR) en_ZA
dc.title Rarβ expression in keratinocytes from potentially malignant oral lesions : the functional consequences of re-expression by de-methylating agents en_ZA
dc.type Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record